Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
58
NMTC Quote, Financials, Valuation and Earnings
Last price:
$0.77
Seasonality move
:
-4.53%
Day range:
$0.70 - $0.78
52-week range:
$0.40 - $1.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.54x
P/B ratio:
5.46x
Volume:
277.2K
Avg. volume:
234.3K
1-year change:
-0.52%
Market cap:
$38.6M
Revenue:
$12.1M
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
$2.5M | -- | -54.48% | -57.14% | $2.23 |
|
IVF
INVO Fertility, Inc.
|
$1.8M | -- | -8.8% | -- | -- |
|
NTRB
Nutriband, Inc.
|
$675K | -$0.17 | 4.52% | -54.85% | $15.00 |
|
NVNO
enVVeno Medical Corp.
|
-- | -$0.28 | -- | -9.68% | $12.50 |
|
SINT
SINTX Technologies, Inc.
|
$200K | -$0.55 | -44.65% | -56.43% | $12.25 |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$2B | $1.87 | 9.9% | 100.01% | $102.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
$0.77 | $2.23 | $38.6M | -- | $0.00 | 0% | 2.54x |
|
IVF
INVO Fertility, Inc.
|
$0.87 | -- | $13.2M | -- | $0.00 | 0% | 0.02x |
|
NTRB
Nutriband, Inc.
|
$4.74 | $15.00 | $57.6M | -- | $0.00 | 0% | 23.65x |
|
NVNO
enVVeno Medical Corp.
|
$0.35 | $12.50 | $7.2M | -- | $0.00 | 0% | 473.07x |
|
SINT
SINTX Technologies, Inc.
|
$3.54 | $12.25 | $13.6M | -- | $0.00 | 0% | 6.00x |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$90.23 | $102.04 | $17.9B | 22.33x | $0.24 | 1.06% | 2.24x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
3.64% | 2.039 | 0.6% | 3.40x |
|
IVF
INVO Fertility, Inc.
|
41.99% | -0.446 | 10.12% | 0.07x |
|
NTRB
Nutriband, Inc.
|
3.31% | 2.796 | 0.32% | 7.07x |
|
NVNO
enVVeno Medical Corp.
|
2.62% | 2.197 | 4.32% | 12.90x |
|
SINT
SINTX Technologies, Inc.
|
45.47% | 1.079 | 22.94% | 1.47x |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
38.87% | -0.489 | 41.53% | 1.20x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies Corp.
|
$1.5M | -$1.4M | -83.42% | -89.54% | -50.02% | -$1.5M |
|
IVF
INVO Fertility, Inc.
|
$492.6K | -$1.6M | -188.23% | -471.28% | -93.08% | -$1.8M |
|
NTRB
Nutriband, Inc.
|
$63K | -$3.9M | -159.71% | -164.64% | -1121.15% | -$1.8M |
|
NVNO
enVVeno Medical Corp.
|
-$120K | -$4.9M | -56.26% | -57.7% | -- | -$4.4M |
|
SINT
SINTX Technologies, Inc.
|
-$66K | -$3.4M | -115.95% | -208.36% | -1612.98% | -$2.6M |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
$1.3B | $330.7M | 4.11% | 6.45% | 16.52% | $267.7M |
NeuroOne Medical Technologies Corp. vs. Competitors
-
Which has Higher Returns NMTC or IVF?
INVO Fertility, Inc. has a net margin of -59.08% compared to NeuroOne Medical Technologies Corp.'s net margin of -150.51%. NeuroOne Medical Technologies Corp.'s return on equity of -89.54% beat INVO Fertility, Inc.'s return on equity of -471.28%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.55.77% -$0.03 $7.3M IVFINVO Fertility, Inc.28.04% -$6.14 $10.1M -
What do Analysts Say About NMTC or IVF?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.23, signalling upside risk potential of 190.55%. On the other hand INVO Fertility, Inc. has an analysts' consensus of -- which suggests that it could grow by 16375.97%. Given that INVO Fertility, Inc. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe INVO Fertility, Inc. is more attractive than NeuroOne Medical Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 IVFINVO Fertility, Inc.0 0 0 -
Is NMTC or IVF More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.703, which suggesting that the stock is 29.673% less volatile than S&P 500. In comparison INVO Fertility, Inc. has a beta of 2.540, suggesting its more volatile than the S&P 500 by 153.97%.
-
Which is a Better Dividend Stock NMTC or IVF?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. INVO Fertility, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or IVF?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.7M, which are larger than INVO Fertility, Inc. quarterly revenues of $1.8M. NeuroOne Medical Technologies Corp.'s net income of -$1.6M is higher than INVO Fertility, Inc.'s net income of -$2.6M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while INVO Fertility, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 2.54x versus 0.02x for INVO Fertility, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.2.54x -- $2.7M -$1.6M IVFINVO Fertility, Inc.0.02x -- $1.8M -$2.6M
-
Which has Higher Returns NMTC or NTRB?
Nutriband, Inc. has a net margin of -59.08% compared to NeuroOne Medical Technologies Corp.'s net margin of -1118.87%. NeuroOne Medical Technologies Corp.'s return on equity of -89.54% beat Nutriband, Inc.'s return on equity of -164.64%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.55.77% -$0.03 $7.3M NTRBNutriband, Inc.18.2% -$0.32 $7.8M -
What do Analysts Say About NMTC or NTRB?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.23, signalling upside risk potential of 190.55%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 216.46%. Given that Nutriband, Inc. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe Nutriband, Inc. is more attractive than NeuroOne Medical Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 NTRBNutriband, Inc.1 0 0 -
Is NMTC or NTRB More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.703, which suggesting that the stock is 29.673% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.907, suggesting its more volatile than the S&P 500 by 90.735%.
-
Which is a Better Dividend Stock NMTC or NTRB?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NTRB?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.7M, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. NeuroOne Medical Technologies Corp.'s net income of -$1.6M is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 2.54x versus 23.65x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.2.54x -- $2.7M -$1.6M NTRBNutriband, Inc.23.65x -- $346.1K -$3.9M
-
Which has Higher Returns NMTC or NVNO?
enVVeno Medical Corp. has a net margin of -59.08% compared to NeuroOne Medical Technologies Corp.'s net margin of --. NeuroOne Medical Technologies Corp.'s return on equity of -89.54% beat enVVeno Medical Corp.'s return on equity of -57.7%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.55.77% -$0.03 $7.3M NVNOenVVeno Medical Corp.-- -$0.23 $30.2M -
What do Analysts Say About NMTC or NVNO?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.23, signalling upside risk potential of 190.55%. On the other hand enVVeno Medical Corp. has an analysts' consensus of $12.50 which suggests that it could grow by 3423.11%. Given that enVVeno Medical Corp. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe enVVeno Medical Corp. is more attractive than NeuroOne Medical Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 NVNOenVVeno Medical Corp.0 1 0 -
Is NMTC or NVNO More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.703, which suggesting that the stock is 29.673% less volatile than S&P 500. In comparison enVVeno Medical Corp. has a beta of 1.063, suggesting its more volatile than the S&P 500 by 6.264%.
-
Which is a Better Dividend Stock NMTC or NVNO?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. enVVeno Medical Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NVNO?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.7M, which are larger than enVVeno Medical Corp. quarterly revenues of --. NeuroOne Medical Technologies Corp.'s net income of -$1.6M is higher than enVVeno Medical Corp.'s net income of -$4.5M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while enVVeno Medical Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 2.54x versus 473.07x for enVVeno Medical Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.2.54x -- $2.7M -$1.6M NVNOenVVeno Medical Corp.473.07x -- -- -$4.5M
-
Which has Higher Returns NMTC or SINT?
SINTX Technologies, Inc. has a net margin of -59.08% compared to NeuroOne Medical Technologies Corp.'s net margin of -1701.44%. NeuroOne Medical Technologies Corp.'s return on equity of -89.54% beat SINTX Technologies, Inc.'s return on equity of -208.36%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.55.77% -$0.03 $7.3M SINTSINTX Technologies, Inc.-31.73% -$3.46 $7.5M -
What do Analysts Say About NMTC or SINT?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.23, signalling upside risk potential of 190.55%. On the other hand SINTX Technologies, Inc. has an analysts' consensus of $12.25 which suggests that it could grow by 246.05%. Given that SINTX Technologies, Inc. has higher upside potential than NeuroOne Medical Technologies Corp., analysts believe SINTX Technologies, Inc. is more attractive than NeuroOne Medical Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 SINTSINTX Technologies, Inc.2 0 0 -
Is NMTC or SINT More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.703, which suggesting that the stock is 29.673% less volatile than S&P 500. In comparison SINTX Technologies, Inc. has a beta of 0.633, suggesting its less volatile than the S&P 500 by 36.717%.
-
Which is a Better Dividend Stock NMTC or SINT?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. SINTX Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or SINT?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.7M, which are larger than SINTX Technologies, Inc. quarterly revenues of $208K. NeuroOne Medical Technologies Corp.'s net income of -$1.6M is higher than SINTX Technologies, Inc.'s net income of -$3.5M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while SINTX Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 2.54x versus 6.00x for SINTX Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.2.54x -- $2.7M -$1.6M SINTSINTX Technologies, Inc.6.00x -- $208K -$3.5M
-
Which has Higher Returns NMTC or ZBH?
Zimmer Biomet Holdings, Inc. has a net margin of -59.08% compared to NeuroOne Medical Technologies Corp.'s net margin of 11.55%. NeuroOne Medical Technologies Corp.'s return on equity of -89.54% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies Corp.55.77% -$0.03 $7.3M ZBHZimmer Biomet Holdings, Inc.62.7% $1.16 $20.9B -
What do Analysts Say About NMTC or ZBH?
NeuroOne Medical Technologies Corp. has a consensus price target of $2.23, signalling upside risk potential of 190.55%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.04 which suggests that it could grow by 13.09%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe NeuroOne Medical Technologies Corp. is more attractive than Zimmer Biomet Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies Corp.1 0 0 ZBHZimmer Biomet Holdings, Inc.4 18 1 -
Is NMTC or ZBH More Risky?
NeuroOne Medical Technologies Corp. has a beta of 0.703, which suggesting that the stock is 29.673% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.541%.
-
Which is a Better Dividend Stock NMTC or ZBH?
NeuroOne Medical Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings, Inc. offers a yield of 1.06% to investors and pays a quarterly dividend of $0.24 per share. NeuroOne Medical Technologies Corp. pays -- of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Zimmer Biomet Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NMTC or ZBH?
NeuroOne Medical Technologies Corp. quarterly revenues are $2.7M, which are smaller than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. NeuroOne Medical Technologies Corp.'s net income of -$1.6M is lower than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, NeuroOne Medical Technologies Corp.'s price-to-earnings ratio is -- while Zimmer Biomet Holdings, Inc.'s PE ratio is 22.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies Corp. is 2.54x versus 2.24x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies Corp.2.54x -- $2.7M -$1.6M ZBHZimmer Biomet Holdings, Inc.2.24x 22.33x $2B $231.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
